IDiyas

For the Inventor, By the Inventor

Killingworth, CT, United States of America

Yonghua Gai

USPTO Granted Patents = 7

Average Co-Inventor Count = 5.9

ph-index = 5

Forward Citations = 70(Granted Patents)


Location History:

  • La Prairie, CA (2001)
  • Killingworth, CT (US) (2002 - 2013)

Company Filing History:

goldMedal7 out of 3,681 
 
Bristol-myers Squibb Compnay
 patents

Years Active: 2001-2013

Loading Chart...
7 patents (USPTO):Explore Patents
1. 8513253 - α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors (2013-08-20),
2. 7786122 - α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors (2010-08-31),
3. 7300936 - α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors (2007-11-27),
4. 6492550 - Alpha-substituted thio, -oxo trifluoromethylketones as phospholipase inhibitors (2002-12-10),
5. 6414179 - Alpha-and beta-substituted trifluoromethyl ketones as phospholipase inhibitors (2002-07-02),
6. 6350892 - Trifluoromethyl ketone analogs as selective cPLA2 inhibitors (2002-02-26),
7. 6255496 - Trifluoromethyl ketone analogs as selective cPLA2 inhibitors (2001-07-03),

Title: The Innovative Contributions of Yonghua Gai

Introduction

Yonghua Gai is a notable inventor based in Killingworth, CT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target Alzheimer's Disease. With a total of 7 patents to his name, Gai's work is recognized for its potential impact on medical treatments.

Latest Patents

Among his latest patents, Gai has developed a series of novel α-(N-sulfonamido)acetamide derivatives that serve as β-amyloid inhibitors. These compounds are designed to inhibit the production of β-amyloid peptide (β-AP), which is crucial in the treatment of Alzheimer's Disease and other conditions influenced by anti-amyloid activity. His innovative approach in this area showcases his commitment to addressing significant health challenges.

Career Highlights

Yonghua Gai is currently associated with Bristol-Myers Squibb Company, where he continues to advance his research and development efforts. His work has not only contributed to the scientific community but also holds promise for improving patient outcomes in neurodegenerative diseases.

Collaborations

Gai has collaborated with esteemed colleagues such as Jacques Banville and Michael Frederick Parker. These partnerships have further enriched his research endeavors and have facilitated the exchange of ideas and expertise in the field.

Conclusion

Yonghua Gai's innovative work in developing β-amyloid inhibitors highlights his significant role in the fight against Alzheimer's Disease. His contributions through his patents and collaborations reflect a dedication to advancing medical science and improving lives.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…